Elucidation of the molecular mechanisms of PD-1 activity and the identification of its ligands (23, 24) has enabled detailed investigation of the involvement of this receptor–ligand pair in the anti-tumor immune response. The gene discussed is PDCD1; the disease is neoplasm.